The latest divestiture comes as the Dallas-based for-profit has sold other hospitals while it reduces its debt load.
Tenet to sell two California hospitals to Adventist for $550M Read More »
FORE Biotherapeutics today announced the appointment of William R. Hinshaw as the Chief Executive Officer and Director of the Board.
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer Read More »
The proposed deal would create a 28-hospital system in New York and Connecticut.
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO ® for RSV in Older Adults.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Janux Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock
Genethon, a non-profit research organization focused on developing gene therapies for rare diseases, marks International Rare Disease Day by highlighting its efforts to bring gene therapies to patients suffering from rare diseases such as limb girdle muscular dystrophies, Crigler Najjar syndrome and Duchenne muscular dystrophy.
BioArctic AB announced that the company and its partner Eisai will present new data on lecanemab at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, to be held in Lisbon, Portugal and virtually, March 5-9.
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress Read More »
Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its participation in the Leerink Partners Global Biopharma Conference, taking place on March 11-13, in Miami, Florida, USA.
Genomma Lab Internacional, S.A.B. de C.V. announced that MSCI, one of the world’s largest providers of indices for tracking companies according to environmental, social and governance criteria, upgraded Genomma’s MSCI ESG Rating to A from BBB.
